These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36824935)

  • 1. Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell Cancer.
    Ko KP; Zhang S; Huang Y; Kim B; Zou G; Jun S; Zhang J; Martin C; Dunbar KJ; Efe G; Rustgi AK; Zhang H; Nakagawa H; Park JI
    bioRxiv; 2023 Feb; ():. PubMed ID: 36824935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor niche network-defined subtypes predict immunotherapy response of esophageal squamous cell cancer.
    Ko KP; Zhang S; Huang Y; Kim B; Zou G; Jun S; Zhang J; Zhao Y; Martin C; Dunbar KJ; Efe G; Rustgi AK; Nakagawa H; Zhang H; Liu Z; Park JI
    iScience; 2024 May; 27(5):109795. PubMed ID: 38741711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PES1 reduces CD8
    Ma N; Hua R; Yang Y; Liu ZC; Pan J; Yu BY; Sun YF; Xie D; Wang Y; Li ZG
    J Biomed Sci; 2023 Mar; 30(1):20. PubMed ID: 36959575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer.
    He JZ; Chen Y; Zeng FM; Huang QF; Zhang HF; Wang SH; Yu SX; Pang XX; Liu Y; Xu XE; Wu JY; Shen WJ; Li ZY; Li EM; Xu LY
    J Exp Clin Cancer Res; 2023 May; 42(1):136. PubMed ID: 37254126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single-cell RNA sequencing.
    Shi K; Li Y; Yang L; Zhang Z; Guo D; Zhang J; Lu Y
    FASEB J; 2022 Nov; 36(11):e22620. PubMed ID: 36260317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma.
    Sui X; Chen C; Zhou X; Wen X; Shi C; Chen G; Liu J; He Z; Yao Y; Li Y; Gao Y
    J Exp Clin Cancer Res; 2023 Feb; 42(1):51. PubMed ID: 36850011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities.
    Zhao N; Zhang Z; Wang Q; Li L; Wei Z; Chen H; Zhou M; Liu Z; Su J
    EBioMedicine; 2023 Oct; 96():104801. PubMed ID: 37725855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.
    Li R; Huang B; Tian H; Sun Z
    Front Oncol; 2022; 12():1096717. PubMed ID: 36698392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progenitor-like exhausted SPRY1
    Liu Z; Zhang Y; Ma N; Yang Y; Ma Y; Wang F; Wang Y; Wei J; Chen H; Tartarone A; Velotta JB; Dayyani F; Gabriel E; Wakefield CJ; Kidane B; Carbonelli C; Long L; Liu Z; Su J; Li Z
    Cancer Cell; 2023 Nov; 41(11):1852-1870.e9. PubMed ID: 37832554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
    Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the single-cell transcriptome network underlying esophagus non-malignant tissues and esophageal squamous cell carcinoma.
    Chen Z; Zhao M; Liang J; Hu Z; Huang Y; Li M; Pang Y; Lu T; Sui Q; Zhan C; Lin M; Guo W; Wang Q; Tan L
    EBioMedicine; 2021 Jul; 69():103459. PubMed ID: 34192657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma.
    Li Y; Xu F; Chen F; Chen Y; Ge D; Zhang S; Lu C
    EBioMedicine; 2021 Aug; 70():103510. PubMed ID: 34365093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
    Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
    Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
    Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative immunotherapy for esophageal squamous cell carcinoma.
    Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
    Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation-Induced Remodeling of the Tumor Microenvironment Through Tumor Cell-Intrinsic Expression of cGAS-STING in Esophageal Squamous Cell Carcinoma.
    Nakajima S; Mimura K; Kaneta A; Saito K; Katagata M; Okayama H; Saito M; Saze Z; Watanabe Y; Hanayama H; Tada T; Sakamoto W; Momma T; Ohira H; Kono K
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):957-971. PubMed ID: 36368436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
    Liu J; Chen H; Qiao G; Zhang JT; Zhang S; Zhu C; Chen Y; Tang J; Li W; Wang S; Tian H; Chen Z; Ma D; Tian J; Wu YL
    Cancer Immunol Immunother; 2023 Apr; 72(4):881-893. PubMed ID: 36121452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative prognostic modeling in ESCC: leveraging scRNA-seq and bulk-RNA for dendritic cell heterogeneity analysis.
    Shi M; Zhang H; Ma L; Wang X; Sun D; Feng Z
    Front Immunol; 2024; 15():1352454. PubMed ID: 38515748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
    Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
    Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.